Humana Inc.

Humana Inc.

HUM

$417.87

Updated: 04/11/2026, 09:37:13

Market Cap
$50.18B
Sector
Healthcare
Industry
Medical - Healthcare Plans
Country
US

No historical data available

Company Profile

Humana Inc., a prominent health and well-being enterprise, operates across the United States through its various subsidiary companies. Its operational structure is divided into three main segments: Retail, Group and Specialty, and Healthcare Services. The firm provides a wide array of medical and supplementary insurance plans directly to individual consumers. Furthermore, Humana collaborates with government entities; it holds a contract with the Centers for Medicare and Medicaid Services (CMS) to manage the Limited Income Newly Eligible Transition (LI NET) prescription drug program. The company also secures agreements with numerous states to deliver Medicaid, dual-eligible, and long-term care support benefits. For employer groups and individuals, Humana furnishes fully insured commercial medical and specialized health coverage, which encompasses dental, vision, and other ancillary health benefits. They additionally offer administrative services only (ASO) solutions and extend support to military personnel through contracts like the TRICARE T2017 East Region. Beyond insurance products, the company delivers comprehensive healthcare services directly. These include pharmacy management, provider network services, and a suite of home-based solutions such as home health care, serving both its own health plan enrollees and external clients. By the close of 2021 (December 31), Humana's reach extended to approximately 17 million individuals enrolled in its medical benefit plans and an additional 5 million utilizing its specialized product offerings. Established in 1961, Humana Inc. maintains its corporate headquarters in Louisville, Kentucky.

USD
NYSE
CEO: James A. Rechtin
Employees: 67,060
https://www.humana.com
Asset Summaries
Latest generated summaries for HUM

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
HUM-10-k-fy2025.html2.9 MBtext/htmlENFiled 19/02/2026Period ended 31/12/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 40 KPI observations

Revenue

N/A

FY — · Reported

Net income

$1.2B

FY 2025 · Reported

Gross margin

N/A

FY — · Reported

Free cash flow

$0.4B

FY 2025 · Calculated

R&D intensity

N/A

FY — · Reported

Share repurchases

$0.2B

FY 2025 · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Reported sales by product or service. Shares and growth are calculated from the filing values.
Product / serviceSalesShare of salesYoY growthBy reported area
total_segment_musd
Source evidence
“Individual Medicare Advantage$90,403 70.3 % ... Total Insurance segment premiums and services revenue$123,842 96.3 %”
123,842N/AN/ANot disclosed by product and area
total_premiums_musd
Source evidence
“Individual Medicare Advantage$90,403 70.3 % ... Total Insurance segment premiums and services revenue$123,842 96.3 %”
122,825N/AN/ANot disclosed by product and area
total_medicare_musd
Source evidence
“Individual Medicare Advantage$90,403 70.3 % ... Total Insurance segment premiums and services revenue$123,842 96.3 %”
106,261N/AN/ANot disclosed by product and area
individual_medicare_advantage_musd
Source evidence
“Individual Medicare Advantage$90,403 70.3 % ... Total Insurance segment premiums and services revenue$123,842 96.3 %”
90,403N/AN/ANot disclosed by product and area
state_based_contracts_and_other_musd
Source evidence
“Individual Medicare Advantage$90,403 70.3 % ... Total Insurance segment premiums and services revenue$123,842 96.3 %”
14,477N/AN/ANot disclosed by product and area
group_medicare_advantage_musd
Source evidence
“Individual Medicare Advantage$90,403 70.3 % ... Total Insurance segment premiums and services revenue$123,842 96.3 %”
9,014N/AN/ANot disclosed by product and area
medicare_stand_alone_pdp_musd
Source evidence
“Individual Medicare Advantage$90,403 70.3 % ... Total Insurance segment premiums and services revenue$123,842 96.3 %”
6,844N/AN/ANot disclosed by product and area
medicare_supplement_musd
Source evidence
“Individual Medicare Advantage$90,403 70.3 % ... Total Insurance segment premiums and services revenue$123,842 96.3 %”
1,098N/AN/ANot disclosed by product and area
military_services_and_other_musd
Source evidence
“Individual Medicare Advantage$90,403 70.3 % ... Total Insurance segment premiums and services revenue$123,842 96.3 %”
1,017N/AN/ANot disclosed by product and area
specialty_benefits_musd
Source evidence
“Individual Medicare Advantage$90,403 70.3 % ... Total Insurance segment premiums and services revenue$123,842 96.3 %”
989N/AN/ANot disclosed by product and area
total_segment_pct
Source evidence
“Individual Medicare Advantage$90,403 70.3 % ... Total Insurance segment premiums and services revenue$123,842 96.3 %”
96.3N/AN/ANot disclosed by product and area
total_premiums_pct
Source evidence
“Individual Medicare Advantage$90,403 70.3 % ... Total Insurance segment premiums and services revenue$123,842 96.3 %”
95.5N/AN/ANot disclosed by product and area
total_medicare_pct
Source evidence
“Individual Medicare Advantage$90,403 70.3 % ... Total Insurance segment premiums and services revenue$123,842 96.3 %”
82.6N/AN/ANot disclosed by product and area
pct
Source evidence
“Individual Medicare Advantage$90,403 70.3 % ... Total Insurance segment premiums and services revenue$123,842 96.3 %”
70.3N/AN/ANot disclosed by product and area
state_based_pct
Source evidence
“Individual Medicare Advantage$90,403 70.3 % ... Total Insurance segment premiums and services revenue$123,842 96.3 %”
11.2N/AN/ANot disclosed by product and area
group_pct
Source evidence
“Individual Medicare Advantage$90,403 70.3 % ... Total Insurance segment premiums and services revenue$123,842 96.3 %”
7N/AN/ANot disclosed by product and area
pdp_pct
Source evidence
“Individual Medicare Advantage$90,403 70.3 % ... Total Insurance segment premiums and services revenue$123,842 96.3 %”
5.3N/AN/ANot disclosed by product and area
supplement_pct
Source evidence
“Individual Medicare Advantage$90,403 70.3 % ... Total Insurance segment premiums and services revenue$123,842 96.3 %”
0.9N/AN/ANot disclosed by product and area
services_pct
Source evidence
“Individual Medicare Advantage$90,403 70.3 % ... Total Insurance segment premiums and services revenue$123,842 96.3 %”
0.8N/AN/ANot disclosed by product and area
specialty_pct
Source evidence
“Individual Medicare Advantage$90,403 70.3 % ... Total Insurance segment premiums and services revenue$123,842 96.3 %”
0.8N/AN/ANot disclosed by product and area

Other offerings mentioned without separate sales

Insurance segment composition
Product portfolio referenced in state regulation

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

How the business makes money

Company overview

Humana Inc., Delaware corporation organized 1964, headquartered in Louisville, Kentucky; operates through Humana insurance services and CenterWell health care services.

99%
Source evidence
“Headquartered in Louisville, Kentucky, Humana Inc. and its subsidiaries, referred to throughout this document as “we,” “us,” “our,” the “Company” or “Humana,” is committed to putting health first”

Company overview

Humana Inc., headquartered in Louisville, Kentucky; Humana insurance services and CenterWell health care services serving Medicare/Medicaid participants, families, individuals, military service personnel

98%
Source evidence
“Humana Inc., headquartered in Louisville, Kentucky, is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services”

Centralized intercompany services

Parent company charges subsidiaries a services fee for centralized services from headquarters and service centers

95%
Source evidence
“Humana Inc., our parent company, charges a services fee for reimbursement of certain centralized services provided to its subsidiaries”

Captive insurance subsidiary

Retains risks via wholly-owned captive insurance subsidiary; buys excess coverage from third-party insurers

95%
Source evidence
“We retain certain of these risks through our wholly-owned, captive insurance subsidiary.”

Reportable segments

Two reportable segments: Insurance and CenterWell, measured by income (loss) from operations.

98%
Source evidence
“Our two reportable segments, Insurance and CenterWell, are based on a combination of the type of health plan customer and adjacent businesses centered on well-being solutions”

Geographic reach of Medicare plans

National Medicare presence: at least one Medicare plan type in all 50 states; over 30 years in Medicare program.

95%
Source evidence
“We have participated in the Medicare program for private health plans for over 30 years and have established a national presence, offering at least one type of Medicare plan in all 50 states.”

Health services operations via affiliated physician-owned professional groups

Subsidiaries use management agreements with physician-owned professional groups that retain responsibility for medical decisions and malpractice insurance

90%
Source evidence
“Under management agreements between certain of our subsidiaries and affiliated physician-owned professional groups, these groups retain sole responsibility for all medical decisions, as well as for hiring and managing physicians and other licensed healthcare providers”

Vertically-integrated and prescription drug benefit businesses

Company operates vertically-integrated assets and prescription drug benefit businesses subject to potential regulation restrictions

80%
Source evidence
“further restrictions on service arrangements and fee payments between intercompany or vertically-integrated assets, increases in regulation of our prescription drug benefit businesses”

Insurance segment composition

Insurance segment: Medicare (individual/group), LI-NET PDP, state-based Medicaid/dual/LTSS contracts, specialty benefits (dental, vision, supplemental), Military services (T-5 East Region), and PBM operations.

97%
Source evidence
“This segment also includes products consisting of specialty health insurance benefits marketed to individuals and employer groups, including dental, vision, and other supplemental health benefits.”

Product portfolio referenced in state regulation

HMOs, PPOs and other health insurance-related products sold under state insurance regulator licenses

90%
Source evidence
“The HMO, PPO, and other health insurance-related products we offer are sold under licenses issued by the applicable insurance regulators.”

Revenue by type

Total revenues $129,664M (2025), $117,761M (2024), $106,374M (2023); premiums $122,825M in 2025

99%
Source evidence
“Premiums$122,825 $112,104 $101,272”

Insurance segment revenue by product (FY2025)

FY2025 Insurance segment premiums and services revenue: Individual MA $90,403M (70.3%); Group MA $9,014M (7.0%); Medicare stand-alone PDP $6,844M (5.3%); Total Medicare $106,261M (82.6%); Specialty benefits $989M; Medicare Supplement $1,098M; State-based contracts and other $14,477M; Total premiums $122,825M; Military services and other services $1,017M; Total $123,842M (96.3% of consolidated).

98%
Source evidence
“Individual Medicare Advantage$90,403 70.3 % ... Total Insurance segment premiums and services revenue$123,842 96.3 %”

Operations and dependencies

Associate headcount

Approximately 67,060 associates as of December 31, 2025

99%
Source evidence
“As of December 31, 2025, we had approximately 67,060 associates.”

Positioning and strategy

Exit of Employer Group Commercial Medical Products business

Finalized exit from Employer Group Commercial Medical Products business in 2025

98%
Source evidence
“During 2025, we finalized our exit from the Employer Group Commercial Medical Products business, which included all fully insured, self-funded and Federal Employee Health Benefit medical plans”

Exit of Employer Group Commercial Medical Products business

Finalized exit from Employer Group Commercial Medical Products business (fully insured, self-funded, FEP medical plans and wellness/rewards) during 2025.

97%
Source evidence
“During 2025, we finalized our exit from the Employer Group Commercial Medical Products business, which included all fully insured, self-funded and Federal Employee Health Benefit medical plans”

Strategic initiatives

Strategy centered on Medicare expansion, state-based contracts, CenterWell growth (pharmacy, primary care, home), and integrated care delivery

97%
Source evidence
“the growth of our pharmacy solutions, primary care, and home solutions businesses, and the successful implementation of our integrated care delivery model”

Multi-year transformation program

Substantial multi-year transformation program to re-align cost structure, operating model and technology footprint

95%
Source evidence
“we initiated a substantial multi-year transformation program designed to re-align our cost structure, operating model and technology footprint with evolving market conditions.”

Integrated care delivery model

Integrated care delivery model uniting quality care, member engagement, and data analytics; supports provider transition from FFS to value-based arrangements.

90%
Source evidence
“At the core of our strategy is our integrated care delivery model, which unites quality care, high member engagement, and sophisticated data analytics.”

Risks, financing, and outlook

Debt balances

Long-term debt $12,369M (2025) up from $11,144M; no short-term debt at YE2025; interest expense $631M

97%
Source evidence
“Long-term debt12,369 11,144”

2025 financing activity

2025: $1,481M net senior note issuance, $948M senior note repayment, $151M buybacks, $430M dividends

96%
Source evidence
“Proceeds from issuance of senior notes, net1,481 2,232 2,544”

Expectation of additional restructuring charges

Company expects to incur additional charges over the course of the transformation program

93%
Source evidence
“We expect to incur additional charges over the course of the program.”

Industry pressures

Management cites sustained macroeconomic, regulatory and competitive pressures impacting the industry, prompting a multi-year transformation program.

90%
Source evidence
“in response to sustained macroeconomic, regulatory and competitive pressures impacting the industry, we initiated a substantial multi-year transformation program”

Certificate of need and regulatory change uncertainty

Cannot predict effect of federal/state legislative and regulatory changes, including CON laws, on results

90%
Source evidence
“Law at the federal level and laws in certain states limiting the entry of new providers or services though a certificate of need, or CON, process.”

Value creation and transformation program charges

$449M/$281M/$436M value creation charges in 2025/2024/2023; $253M additional impairments in 2025; multi-year transformation program ongoing

97%
Source evidence
“we recorded charges of $449 million, $281 million and $436 million in 2025, 2024 and 2023, respectively, primarily within operating costs in the consolidated statements of income. We expect to incur additional charges over the course of the program.”

Value creation initiatives and transformation program charges

Multi-year transformation program: charges of $449M (2025), $281M (2024), $436M (2023); plus impairment charges of $253M/$200M/$91M; additional charges expected.

96%
Source evidence
“we recorded charges of $449 million, $281 million and $436 million in 2025, 2024 and 2023, respectively... We expect to incur additional charges over the course of the program.”

Government policy dependence for Medicare/Medicaid/TRICARE

Government policies on Medicare Advantage, PDP, military services, and Medicaid substantially impact profitability

96%
Source evidence
“The policies and decisions of the federal and state governments regarding the Medicare Advantage and Prescription Drug Plans, military services and Medicaid programs in which we participate have a substantial impact on our profitability.”

Major healthcare reform laws affecting business

ACA, Families First Act, CARES Act, and Inflation Reduction Act of 2022 enacted significant reforms to U.S. health insurance including MA premium adjustments and Part D design changes

95%
Source evidence
“the Patient Protection and Affordable Care Act and The Health Care and Education Reconciliation Act of 2010 (which we collectively refer to as the Health Care Reform Law), the Families First Coronavirus Response Act (the “Families First Act”), the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), and the Inflation Reduction Act of 2022”

HIPAA and HITECH Act privacy/data security regulation

HIPAA/HITECH impose PHI breach reporting (including media notification when 500+ impacted) and privacy/security compliance costs with criminal/civil penalties

95%
Source evidence
“to notify the media in any states where 500 or more people are impacted by any unauthorized release or use of or access to PHI, requires business associates to comply with certain provisions of the HIPAA privacy and security rule”

State regulation of HMO/PPO insurance products

State laws regulate HMOs, PPOs and insurance services including licensing, rate increases, enrollment, and dividend approvals; licensed subsidiaries also subject to Puerto Rico regulations

90%
Source evidence
“Laws in each of the states in which we operate our HMOs, PPOs and other health insurance-related services regulate our operations including: capital adequacy and other licensing requirements, policy language describing benefits, mandated benefits and processes”

Benefits expense estimation and pricing risk

Fixed one-year premiums with actuarially estimated benefits expense create margin risk if medical costs exceed projections

98%
Source evidence
“Generally, premiums in the health care business are fixed for one-year periods. Accordingly, costs we incur in excess of our benefit cost projections generally are not recovered in the contract year through higher premiums.”

Star Ratings decline and 2026 quality bonus risk

Significant 2025 Star Ratings decline threatens 2026 CMS quality bonus payments; lawsuit filed against CMS ratings

98%
Source evidence
“If we are not successful, the decline in our Star Ratings will negatively impact our 2026 quality bonus payments from CMS and may also significantly adversely affect our revenues, operating results, and cash flows.”

Medicare revenue concentration

Concentration of revenues in Medicare products intensifies risk

97%
Source evidence
“the attendant concentration of revenues intensifies the risks to us inherent in Medicare products”

Fraud and abuse laws (False Claims Act, Anti-Kickback Statute, Stark Law)

Violations could result in recoupment, civil penalties, treble damages, or exclusion from Medicare/Medicaid

95%
Source evidence
“Potential sanctions for violating these laws include recoupment or reduction of government reimbursement amounts, civil penalties, treble damages, and exclusion from participating in the Medicare and Medicaid programs”

Cost drivers of medical costs

Disclosed list of factors causing actual health care costs to exceed pricing estimates

95%
Source evidence
“Many factors may and often do cause actual health care costs to exceed what was estimated and used to set our premiums.”

Litigation and regulatory sanction exposure

Reasonably possible that litigation, penalties, fines or other sanctions could be substantial and materially adverse

95%
Source evidence
“it is reasonably possible that any such outcome of litigation, penalties, fines or other sanctions could be substantial, and the outcome of these matters may have a material adverse effect on our results of operations, financial position, and cash flows”

Competition and low entry barriers

Highly competitive industry; low barriers to entry; price competition and member switching flexibility via Medicare AEP

95%
Source evidence
“We believe that barriers to entry in our markets are not substantial, so the addition of new competitors can occur relatively easily, and customers enjoy significant flexibility in moving between competitors through the Medicare Annual Enrollment Period.”

Legislative/regulatory change risk to Medicare revenue

Regulatory changes may restrict revenue, enrollment and premium growth, raise medical/operating costs, and further lower Medicare payment rates

95%
Source evidence
“restricting revenue, enrollment and premium growth in certain products and market segments, restricting our ability to expand into new markets, increasing our medical and operating costs, further lowering our Medicare payment rates and increasing our expenses associated with assessments”

Information systems and AI/ML dependency

Significant dependency on information systems and AI/ML technologies with ongoing investment needs

94%
Source evidence
“including systems powered by or incorporating artificial intelligence and machine learning (including generative AI) (AI/ML), to keep pace with continuing changes in information processing technology”

Consolidation of affiliated medical practices (VIEs)

Consolidates affiliated P.A. medical practices as VIEs under exclusive management agreements despite not owning many practices

94%
Source evidence
“We do not own many of our medical practices but instead enter into exclusive management agreements with the affiliated Professional Associations, or P.A.s, that operate these medical practices.”

M&A execution risk

Frequent acquisitions/divestitures strategy; failure to manage integration could materially harm results

90%
Source evidence
“Any failure by us to manage acquisitions, divestitures and other significant transactions successfully may have a material adverse effect on our results of operations, financial position, and cash flows.”

Certificate of Need (CON) requirements

CON state requirements can restrict expansion; elimination of CON could impair associated intangible value

90%
Source evidence
“To the extent laws in these CON states change, including the elimination of the CON requirement, the intangible value associated with these CONs may be impaired.”

Corporate Practice of Medicine exposure

State corporate practice of medicine/fee-splitting statutes; enforcement could force restructuring with material adverse effect

90%
Source evidence
“any enforcement actions by governmental officials alleging non-compliance with these statutes, which could subject us to penalties or restructuring or reorganization of our business, may result in a material adverse effect on our results of operations, financial position, or cash flows”

Material exposure graph

U.S. federal government (CMS)
Customer Exposure

~83% of premiums and services revenue comes from federal government contracts; 14% tied to CMS Medicare Advantage in Florida.

Relevance 98·Dependency 95·Confidence 99
Source evidence
“We derived approximately 83% of our total premiums and services revenue from contracts with the federal government in 2025, including 14% related to our federal government contracts with the Centers for Medicare and Medicaid Services, or CMS”
U.S. federal government (CMS)
Customer Exposure

83% of 2025 premiums and services revenue derives from federal government contracts; 14% from CMS individual MA contracts in Florida alone.

Relevance 98·Dependency 83·Confidence 99
Source evidence
“During 2025, 83% of our total premiums and services revenue were derived from contracts with the federal government”
Medicare Advantage regulation
Regulatory Exposure

Changes to Medicare Advantage premiums/payment rates directly affect Humana's core revenue and medical cost structure.

Relevance 95·Dependency 90·Confidence 95
Source evidence
“adjustments to Medicare Advantage premiums”
Federal/state Medicare and Medicaid policy
Revenue Exposure

Government policies shape premiums/revenues, member eligibility and enrollment, services, and administrative and health care costs across Medicare Advantage, PDP, military services, and Medicaid programs.

Relevance 95·Dependency 90·Confidence 97
Source evidence
“These governmental policies and decisions, which we cannot predict with certainty, directly shape the premiums or other revenues to us under the programs”
CMS Star Ratings
Regulatory Exposure

2025 Star Ratings decline directly threatens 2026 CMS quality bonus payments and could significantly adversely affect revenues, operating results, and cash flows.

Relevance 95·Dependency 85·Confidence 98
Source evidence
“the decline in our Star Ratings will negatively impact our 2026 quality bonus payments from CMS and may also significantly adversely affect our revenues, operating results, and cash flows”
Medicare Advantage
Revenue Exposure

Individual Medicare Advantage is the largest product family at $90,403M (70.3% of consolidated premiums and services revenue) with ~5.2 million members.

Relevance 95·Dependency 82·Confidence 97
Source evidence
“Individual Medicare Advantage$90,403 70.3 %”
United States
Revenue Exposure

Medicare product family accounts for 82.6% of consolidated premiums and services revenue, entirely U.S. federal program revenue dependent on CMS payment policy.

Relevance 95·Dependency 80·Confidence 95
Source evidence
“Total Medicare106,261 82.6 %”
CMS Medicare program
Regulatory Exposure

Medicare risk adjustment provisions related to CMS contracts are a critical accounting estimate, exposing results to regulatory changes.

Relevance 92·Dependency 85·Confidence 94
Source evidence
“the impact of risk adjustment provisions related to our Medicare contracts”
Health Care Reform Law (ACA)
Regulatory Exposure

ACA-era reforms impose benefit ratio rebates, guaranteed issuance, and plan design requirements on Humana's insurance products.

Relevance 90·Dependency 85·Confidence 95
Source evidence
“mandated coverage requirements, mandated benefits and guarantee issuance associated with commercial medical insurance, rebates to policyholders based on minimum benefit ratios”
2025 Star Ratings lawsuit
Legal Exposure

Litigation against CMS over 2025 Star Ratings creates uncertain outcome; losing would cement the negative impact on 2026 quality bonus payments and membership/profit margins.

Relevance 90·Dependency 80·Confidence 95
Source evidence
“our plans may not be eligible for full level quality bonuses or may not match the performance of our competitors, each of which could materially and adversely affect the benefits such plans can offer, reduce membership and/or reduce profit margins”
Medical cost inflation
Revenue Exposure

Medical cost inflation is a named driver that can cause actual health care costs to exceed premiums, which are fixed for one-year periods and cannot be repriced mid-year.

Relevance 90·Dependency 80·Confidence 95
Source evidence
“premiums in the health care business are fixed for one-year periods. Accordingly, costs we incur in excess of our benefit cost projections generally are not recovered in the contract year through higher premiums”
CMS risk-adjustment model (BBA/BIPA)
Regulatory Exposure

MA premium payments are risk-adjusted by CMS based on provider-submitted diagnosis codes; coding accuracy directly affects revenue.

Relevance 90·Dependency 75·Confidence 92
Source evidence
“Under the risk-adjustment methodology, all MA plans must collect from providers and submit the necessary diagnosis code information to CMS within prescribed deadlines.”
False Claims Act / Anti-Kickback Statute / Stark Law
Legal Exposure

Fraud and abuse law violations could lead to exclusion from Medicare and Medicaid programs, the payer base for Humana's core business.

Relevance 85·Dependency 80·Confidence 95
Source evidence
“exclusion from participating in the Medicare and Medicaid programs or other government healthcare programs”
Prescription drugs (including specialty)
Cost Driver

Increased use or cost of prescription drugs, including specialty drugs, and changes in pharmacy volume rebates from drug manufacturers are disclosed drivers of medical cost overruns.

Relevance 85·Dependency 75·Confidence 92
Source evidence
“increased use or cost of prescription drugs, including specialty prescription drugs;”
Florida (geographic concentration)
Revenue Exposure

Florida individual MA contracts with CMS represent ~$17.8 billion premiums, ~20% of individual MA premiums and 14% of consolidated premiums and services revenue.

Relevance 85·Dependency 70·Confidence 97
Source evidence
“Florida contracts accounted for premiums revenue of approximately $17.8 billion, which represented approximately 20% of our individual Medicare Advantage premiums revenue, or 14% of our consolidated premiums and services revenue”
Humana Inc.
Cost Driver

Medical benefits expense is the dominant cost; benefits payable estimation is a critical estimate.

Relevance 82·Dependency 70·Confidence 92
Source evidence
“The areas involving the most significant use of estimates are the estimation of benefits payable”
Inflation Reduction Act of 2022
Regulatory Exposure

The Inflation Reduction Act changed the Part D prescription drug benefit design, relevant to Humana's Part D and prescription drug benefit businesses.

Relevance 80·Dependency 75·Confidence 90
Source evidence
“changes to the Part D prescription drug benefit design (and uncertainty arising from the implementation of these changes) may have a material adverse effect on our results of operations”
AI/ML information systems
Technology Dependency

Pricing, service, product innovation, claims payment efficiency, and financial reporting depend significantly on information systems, requiring ongoing significant investment including AI/ML (including generative AI) systems.

Relevance 80·Dependency 75·Confidence 90
Source evidence
“Our ability to adequately price our products and services, provide effective and efficient service to our customers, develop new and innovative products and services... depends significantly on the performance of, and integrity of the data, in our information systems”
HIPAA/HITECH Act
Regulatory Exposure

HIPAA/HITECH govern use of individually identifiable health data, requiring systems enhancements, training, and exposing Humana to penalties including for business associates.

Relevance 80·Dependency 75·Confidence 95
Source evidence
“Compliance with HIPAA and other privacy regulations requires significant systems enhancements, training and administrative effort. HIPAA can also expose us to additional liability for violations by our business associates”
Regulatory and competitive pressures
Demand Driver

Sustained macroeconomic, regulatory and competitive pressures drove the transformation program and impairments.

Relevance 78·Dependency 65·Confidence 90
Source evidence
“in response to sustained macroeconomic, regulatory and competitive pressures impacting the industry”
State insurance regulation
Regulatory Exposure

State holding company regulations require prior approval for dividends, asset transactions, and intercompany agreements, affecting capital flexibility.

Relevance 75·Dependency 70·Confidence 90
Source evidence
“These regulations generally require, among other things, prior approval and/or notice of new products, rates, benefit changes, and certain material transactions, including dividend payments”
Florida
Revenue Exposure

14% of premiums/services revenue tied to CMS contracts for individual Medicare Advantage members in Florida.

Relevance 72·Dependency 68·Confidence 92
Source evidence
“including 14% related to our federal government contracts with the Centers for Medicare and Medicaid Services, or CMS, to provide health insurance coverage for individual Medicare Advantage members in Florida”
State-based contracts (Medicaid, dual eligible, LTSS)
Revenue Exposure

State-based contracts and other premiums of $14,477M (11.2% of consolidated) from Medicaid, dual eligible demonstration, and LTSS contracts with various states.

Relevance 72·Dependency 55·Confidence 93
Source evidence
“contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which we refer to collectively as our state-based contracts”
Corporate practice of medicine statutes
Legal Exposure

Humana's health services delivery model relies on management agreements with physician-owned groups to comply with state corporate practice of medicine laws.

Relevance 70·Dependency 65·Confidence 90
Source evidence
“business corporations generally may not exercise control over the medical decisions of physicians”
Medicare Part D (PDP)
Revenue Exposure

Medicare stand-alone PDP premiums of $6,844M (5.3% of consolidated), plus Part D embedded in most MA plans.

Relevance 70·Dependency 60·Confidence 90
Source evidence
“Medicare stand-alone PDP6,844 5.3 %”
Humana Inc.
Legal Exposure

Commitments and contingencies noted in balance sheet (Note 17), signaling potential legal/contingent liabilities.

Relevance 70·Dependency 60·Confidence 85
Source evidence
“Commitments and contingencies (Note 17)”
Catastrophes/climate change
Revenue Exposure

Catastrophes such as terrorism, public health emergencies, epidemics/pandemics, or natural disasters (hurricanes, earthquakes), potentially intensified by global climate change, may cause costs to exceed estimates.

Relevance 70·Dependency 55·Confidence 88
Source evidence
“catastrophes, including acts of terrorism, public health emergencies, epidemics or pandemics (such as COVID-19), or natural disasters (such as hurricanes and earthquakes) which could occur more frequently or with more intense effects as a result of the impact of global climate change”
Workforce optimization / labor costs
Cost Driver

Severance and workforce optimization charges dominate value creation initiative charges ($329M in 2025), reflecting cost restructuring aimed at funding growth.

Relevance 68·Dependency 50·Confidence 90
Source evidence
“The value creation initiative charges primarily relate to $329 million, $25 million and $199 million in severance and other employee related charges in connection with workforce optimization”
Humana Inc.
Cost Driver

Workforce optimization severance charges ($329M in 2025) are a material component of restructuring charges.

Relevance 65·Dependency 55·Confidence 88
Source evidence
“$329 million, $25 million and $199 million in severance and other employee related charges in connection with workforce optimization in 2025, 2024 and 2023, respectively”
Technology footprint
Technology Dependency

Transformation program includes re-aligning the technology footprint.

Relevance 60·Dependency 55·Confidence 85
Source evidence
“designed to re-align our cost structure, operating model and technology footprint with evolving market conditions”
Full company information
Latest profile, trading, valuation, and identifier data stored for HUM.
Share price
$417.87
Market cap
$50.18B
Exchange
NYSE
Currency
USD
CEO
James A. Rechtin
Employees
67,060
IPO date
31/12/1981
Beta
0.744
Last dividend
$0.00
Day range
$407.36 – $422.65
52-week range
$163.11 – $456.50
1-day performance
1.82%
1-year performance
156.19%
Current drawdown (1Y)
-8.46%
CIK
0000049071
CUSIP
444859102
ISIN
US4448591028
Created
07/12/2025, 04:36:52
Last update
04/11/2026, 09:37:13

Track Humana Inc. with an AI analyst

See which prediction-market events move HUM, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to HUM from your Railway `news_articles` table.

Humana Closes the Kindred Chapter With $900 Million Gentiva Exit

Zacks Investment Research • STOCK • 11/06/2026, 16:21:03

Humana To Divest End-Of-Life Care Business For $900 Million

Forbes • STOCK • 10/06/2026, 20:30:41

Humana divests minority stake in hospice provider Gentiva

Reuters • STOCK • 10/06/2026, 18:53:33

Humana Announces Agreement to Divest Minority Interest in Gentiva

Business Wire • STOCK • 10/06/2026, 18:30:00

Humana and CenterWell Employees Donate More Than $1.4 Million in 24 Hours

Business Wire • STOCK • 10/06/2026, 11:00:00

As Tech Stocks Slide, The Healthcare Sector Shines. Why Some Experts Say They Like This Defensive Play

Investopedia • STOCK • 09/06/2026, 20:06:29

Did Humana Inc. Insiders Breach their Fiduciary Duties to Shareholders?

PRNewsWire • STOCK • 05/06/2026, 17:50:00

Humana Jumps 6%, UnitedHealth Climbs 5%, Cigna Rises 4% as Analysts Cheer Softer Medical Cost Trends

24/7 Wall Street • STOCK • 04/06/2026, 15:32:55

Humana Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humana Inc. - HUM

GuruFocus • STOCK • 30/05/2026, 01:00:00

Humana Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humana Inc. - HUM

PRNewsWire • STOCK • 30/05/2026, 00:00:00

Humana Just Ripped 48% in a Month. Is It Outperforming Other Healthcare Stocks Like UnitedHealth and Cigna?

24/7 Wall Street • STOCK • 18/05/2026, 16:48:21

Humana: Perhaps The 'Buy The Dip' Thesis Was Right All Along (Rating Upgrade)

Seeking Alpha • STOCK • 18/05/2026, 15:49:25